According to the American Lung Association, adults get an average of 2-4 colds annually, mostly between September and May and children may suffer from an average of 6-8 colds each year. The treatment for the common cold includes over-the-counter medications to reduce the symptoms. Antibiotics are administered to fight infections caused by bacteria. Several clinical trials are underway to develop innovative common cold therapeutics to improve and manage the condition. For instance, CM5321 is a potential treatment for the common cold and will be administered as a nasal spray.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing common cold development activities are covered in the report.
There is no cure for a cold as most colds go away on their own in ten days. Since viruses cause colds, antibiotics do not work for colds. Common cold therapeutics includes over-the-counter medications to reduce symptoms, including, pain relievers such as acetaminophen and NSAIDs such as ibuprofen to relieve headaches and fever. Decongestants are also given such as pseudoephedrine, and antihistamines among others. Additionally, cough suppressants are also administered such as dextromethorphan and codeine to reduce coughing. Several pharma companies and research institutes are developing innovative common cold emerging drugs to manage the condition. For instance, G.ST Antivirals GmbH is currently conducting a phase II study for 2-DG-02 for the prevention of rhinovirus-associated illness. The increasing clinical trials and changing dynamics are impacting the clinical trial landscape significantly.
This product will be delivered within 3-5 business days.
Report Coverage
The Common Cold Pipeline Report by the publisher gives comprehensive insights into common cold drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for the common cold. The common cold pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from common cold.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing common cold development activities are covered in the report.
Common Cold Drug Pipeline Outlook
Cold is a contagious upper respiratory infection which affects body areas like the throat, nose, sinuses, and trachea. There are several types of viruses which can cause a cold and the most common cold virus is the rhinovirus which causes up to 50% of common colds. The symptoms of the common cold appear in stages. Stage 1, called early stage, has symptoms like sneezing, cough, stuffy nose, and nasal congestion, among others. Stage 2 is called an active stage. It has symptoms like body aches, headache, fatigue along with runny eyes and nose among others. Stage 3 is called late stage, and some symptoms can persist.There is no cure for a cold as most colds go away on their own in ten days. Since viruses cause colds, antibiotics do not work for colds. Common cold therapeutics includes over-the-counter medications to reduce symptoms, including, pain relievers such as acetaminophen and NSAIDs such as ibuprofen to relieve headaches and fever. Decongestants are also given such as pseudoephedrine, and antihistamines among others. Additionally, cough suppressants are also administered such as dextromethorphan and codeine to reduce coughing. Several pharma companies and research institutes are developing innovative common cold emerging drugs to manage the condition. For instance, G.ST Antivirals GmbH is currently conducting a phase II study for 2-DG-02 for the prevention of rhinovirus-associated illness. The increasing clinical trials and changing dynamics are impacting the clinical trial landscape significantly.
Common Cold - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of common cold drugs based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The common cold therapeutic assessment covers 50+ drug analyses based on drug classes:
- Small Molecule
- Cell Therapy
- Peptides
- Polymer
- Small Molecule
- Gene Therapy
By Route of Administration
The common cold clinical assessment covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Common Cold - Pipeline Assessment Segmentation, By Phases
The common cold report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for the common cold.Common Cold - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under common cold pipeline analysis include small molecule, cell therapy, peptides, polymer, small molecule, and gene therapy. According to NCBI, as of April 2021, there were 126 small-molecule drug trials with various stages for the potential treatment of COVID-19 in at least 700 clinical trials. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for common cold.Common Cold Clinical Trials Assessment - Competitive Dynamics
The common cold report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in common cold clinical trials:_x000D_GlaxoSmithKline
- Laboratorios Silanes S.A. de C.V.
- Sandoz
- Enzymatica AB
- Xigo Health LLC
- Lallemand Pharma AG
- Bayer
- Eli Lilly and Company
- Boehringer Ingelheim
- Novartis
- McNeil AB
- PPC Pharmaceuticals
- Nycomed
- HALEON
- Others
Common Cold - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and common cold therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming common cold drug candidates.Drug: Paracetamol and Caffeine
The trial is designed to investigate if there is any improvement in performance based on cognitive function and mood assessment in patients suffering from the common cold while taking paracetamol and caffeine combination. The trial is sponsored by GlaxoSmithKline and is currently under phase IV.Drug: Ibuprofen + Loratadine fixed dose
The objective of the study is to assess the safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as a monotherapy treatment for the common cold. The trial is sponsored by Laboratorios Silanes S.A. de C.V. and is currently under phase III.Drug: Nasal Glucagon
Eli Lilly and Company is developing the common cold drug candidate and is currently under phase I. The study is being conducted to assess the safety of nasal glucagon in participants with a common cold.Reasons To Buy This Report
The Common Cold Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for common cold. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within common cold pipeline insight.Key Questions Answered in the Common Cold - Pipeline Assessment Report
- What is the current landscape of common cold disease pipeline drugs?
- Which companies/institutions are developing common cold disease emerging drugs?
- How many phase II drugs are currently present in common cold disease pipeline drugs?
- Which company is leading the common cold disease pipeline development activities?
- What is the current common cold disease therapeutic assessment?
- What are the opportunities and challenges present in the common cold disease drug pipeline landscape?
- What is the efficacy and safety profile of common cold disease pipeline drugs?
- Which companies/institutions are involved in common cold disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in common cold disease?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Common Cold
4 Patient Profile: Common Cold
5 Common Cold: Epidemiology Snapshot
6 Common Cold: Market Dynamics
7 Common Cold: Key Facts Covered
8 Common Cold, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Common Cold Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Common Cold Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Common Cold Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Common Cold Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Common Cold, Key Drug Pipeline Companies
16 Terminated or Suspended Pipeline Products
